MedPath

Isoniazid

Generic Name
Isoniazid
Brand Names
Isonarif, Isotamine, Isotamine B, Rifamate, Rifater
Drug Type
Small Molecule
Chemical Formula
C6H7N3O
CAS Number
54-85-3
Unique Ingredient Identifier
V83O1VOZ8L
Background

Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

Indication

Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.

Associated Conditions
Active Tuberculosis, Mycobacterium kansasii infection, Late phase Tuberculosis
Clinical Trials
Related News

Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women

Phase 4
Completed
Conditions
Tuberculosis
HIV Infections
Interventions
Drug: Placebo for isoniazid (INH)
First Posted Date
2011-12-16
Last Posted Date
2021-11-05
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
956
Registration Number
NCT01494038
Locations
🇧🇼

Gaborone CRS, Gaborone, Botswana

🇧🇼

Molepolole CRS, Gaborone, Botswana

🇭🇹

Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti

and more 10 locations

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

Phase 3
Completed
Conditions
Tuberculosis
HIV Infections
Interventions
Dietary Supplement: Pyridoxine (Vitamin B6)
First Posted Date
2011-07-28
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
3000
Registration Number
NCT01404312
Locations
🇺🇸

University of Southern California CRS, Los Angeles, California, United States

🇺🇸

University of Washington AIDS CRS, Seattle, Washington, United States

🇺🇸

Trinity Health and Wellness Center CRS, Dallas, Texas, United States

and more 42 locations

Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)

Phase 3
Conditions
Latent Tuberculosis Infection
Interventions
First Posted Date
2011-07-20
Last Posted Date
2011-07-20
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
300
Registration Number
NCT01398618
Locations
🇨🇳

Chest Hospital, Department of Health, Executive Yuan, Tainan, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment

Phase 4
Completed
Conditions
HIV Infection
Interventions
Drug: Rifampin/isoniazid/pyrazinamide/ethambutol FDC
Drug: Rifampin/isoniazid FDC
First Posted Date
2011-06-27
Last Posted Date
2024-10-14
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
851
Registration Number
NCT01380080
Locations
🇮🇳

BJ Medical College CRS, Pune, Maharashtra, India

🇮🇳

YRG CARE Medical Ctr., VHS Chennai CRS, Rajiv Gandhi Salai Taramani, Chennai, India

🇭🇹

GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS, Port Au Prince, Haiti

and more 15 locations

Acquired Immunodeficiency Syndrome(AIDS) and Tuberculosis(Tb) Co-infection Treatment Strategies Study of China.

Not Applicable
Conditions
AIDS
Interventions
First Posted Date
2011-04-28
Last Posted Date
2011-04-28
Lead Sponsor
Shanghai Public Health Clinical Center
Target Recruit Count
400
Registration Number
NCT01344148
Locations
🇨🇳

Shanghai Public Health Clinical Center, Shanghai, Shanghai, China

Study of Pre-clearance of Latent Tuberculosis Infection And BCG Revaccination

Phase 1
Completed
Conditions
Tuberculosis
Interventions
Biological: BCG strain Danish
First Posted Date
2010-05-07
Last Posted Date
2017-01-09
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
82
Registration Number
NCT01119521
Locations
🇿🇦

University of Cape Town - Institute of Infectious Disease and Molecular Medicine, Cape Town, Western Cape, South Africa

Isoniazid (INH) Treatment Based on ELISPOT Assay

Not Applicable
Completed
Conditions
Kidney Transplant Recipient
Interventions
First Posted Date
2010-03-16
Last Posted Date
2013-12-12
Lead Sponsor
Asan Medical Center
Target Recruit Count
831
Registration Number
NCT01087190
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness

Phase 3
Completed
Conditions
Latent Tuberculosis Infection
Interventions
First Posted Date
2009-07-02
Last Posted Date
2017-12-19
Lead Sponsor
McGill University
Target Recruit Count
6031
Registration Number
NCT00931736
Locations
🇦🇺

Woolcock Institute of Medical Research, Sydney, New South Wales, Australia

🇬🇭

Research and Development Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana

🇬🇳

Service de Phtisiologie, Hopital National Ignace Deen, Conakry, Guinea

and more 9 locations

Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis

First Posted Date
2009-01-01
Last Posted Date
2019-12-09
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
19
Registration Number
NCT00816426
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

🇰🇷

Pusan National Unversity Hospital (PNUH), Busan, Korea, Republic of

🇰🇷

National Medical Center, Seoul, Korea, Republic of

Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison

Phase 3
Completed
Conditions
Tuberculosis
Interventions
Drug: rifampin, randomized, open label
First Posted Date
2008-10-07
Last Posted Date
2010-11-29
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
2384
Registration Number
NCT00767975
Locations
🇨🇳

Taipei Prison, Taoyuan, Taiwan

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy